Monoclonal antibodies in asthma

E-poster session
Chairs: P. Berger (Bordeaux, France), A. Licari (Pavia (PV), Italy)

Differences in the response to treatment with monoclonal antibodies according to age A. Gomez-Larrauri (Barakaldo-Bizkaia, Spain), B. Ortiz De Urbina (Barakaldo-Bizkaia, Spain), J. Andia (Barakaldo-Bizkaia, Spain), E. Garay (Barakaldo-Bizkaia, Spain), A. Rezola (Barakaldo-Bizkaia, Spain), S. Pedrero (Barakaldo-Bizkaia, Spain), P. Sobradillo (Barakaldo-Bizkaia, Spain), E. Lopez De Santamaría (Barakaldo-Bizkaia, Spain), L. Martínez (Barakaldo-Bizkaia, Spain), M. Iriberri (Barakaldo-Bizkaia, Spain), N. Marina (Barakaldo-Bizkaia, Spain)
Clinical indicators of treatment response to Mepolizumab at 12 weeks Y. Pang (Nottingham, United Kingdom), I. Stewart (Nottingham, United Kingdom), T. Harrison (Nottingham, United Kingdom), I. Sayers (Nottingham, United Kingdom), D. Shaw (Nottingham, United Kingdom)
Mepolizumab in real-life treatment of severe eosinophilic asthma E. Voláková (Olomouc 9, Czech Republic), J. Zatloukal (Olomouc 9, Czech Republic)
Real world outcomes of Mepolizumab for severe asthma in Wales a retrospective analysis. A. Harries (Cardiff, United Kingdom), K. Pink (Cardiff, United Kingdom)
Mepolizumab reduces nasal symptoms in asthmatic patients with chronic rhino-sinusitis and nasal polyposis: a 12 months real-life study M. Maniscalco (Telese (BN), Italy), A. Detoraki (Napoli (NA), Italy), M. D’Amato (Napoli (NA), Italy), R. Giacco (Napoli (NA), Italy), C. Calabrese (Napoli (NA), Italy), . Boccia (Napoli (NA), Italy), E. Tremante (Napoli (NA), Italy), R. Poto (Napoli (NA), Italy), G. Quaremba (Napoli (NA), Italy), G. Spadaro (Napoli (NA), Italy)
Evolution of patients with severe asthma treated with mepolizumab A. Martinez Mesa (Malaga, Spain), E. Cabrera Cesar (Malaga, Spain), A. Aguilar Galvez (Malaga, Spain), N. Reina Marfil (Malaga, Spain), E. Sanchez Alvarez (Malaga, Spain), M. Fernandez Aguirre (Malaga, Spain)
Effetiveness of biological treatment in severe asthma difficult to control (SADC) M. Morón Ortiz (Huelva, Spain), J. Hilares Vera (Huelva, Spain), J. Lancha Dominguez (Huelva, Spain), C. Puchaes Manchón (Huelva, Spain), J. Sánchez-Ramos (Huelva, Spain), A. Pereira Vega (Huelva, Spain)
Omalizumab versus mepolizumab in severe asthma: a propensity score matched efficiency retrospective cohort study C. Claudia (Catania, Italy), R. Campisi (Catania, Italy), S. Nolasco (Catania, Italy), E. Heffler (Milano, Italy), G. Valenti (Palermo, Italy), C. Pelaia (Catanzaro, Italy), A. Noto (Messina, Italy), G. Pelaia (Catanzaro, Italy), N. Crimi (Catania, Italy)
Effectiveness of Mepolizumab in Reducing Asthma Exacerbations in Japan H. Nagase (Tokyo, Japan), J. Tamaoki (Tokyo, Japan), T. Suzuki (Tokyo, Japan), Y. Nezu (Tokyo, Japan), A. Cole (Collegeville, United States of America), S. Yang (Collegeville, United States of America), G. Mu (Collegeville, United States of America), M. Katsumata (Tokyo, Japan), M. Komatsubara (Tokyo, Japan), R. Alfonso (Collegeville, United States of America)
Predictor of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study T. Numata (Tokyo, Japan), H. Miyagawa (Tokyo, Japan), K. Okuda (Tokyo, Japan), H. Utsumi (Tokyo, Japan), M. Hashimoto (Tokyo, Japan), S. Minagawa (Tokyo, Japan), T. Ishikawa (Tokyo, Japan), H. Hara (Tokyo, Japan), J. Araya (Tokyo, Japan), K. Kuwano (Tokyo, Japan)
The characteristics of treatment failure with omalizumab in patients with severe asthma: The impact of eosinophilic complication T. Akaba (Tokyo, Japan), M. Kondo (Tokyo, Japan), A. Kurokawa (Tokyo, Japan), K. Takeyama (Tokyo, Japan), E. Tagaya (Tokyo, Japan)
Benralizumab for severe asthma associated with extra-airway eosinophilic diseases M. Toyoshima (Hamamatsu, Japan), K. Koda (Hamamatsu, Japan), T. Nozue (Hamamatsu, Japan), T. Suda (Hamamatsu, Japan)
ABPA relapse after discontinuation of omalizumab C. Bucca (Torino (TO), Italy), L. Brussino (Torino (TO), Italy), I. Ridolfi (Torino (TO), Italy), S. Nicola (Torino (TO), Italy), G. Rolla (Torino (TO), Italy)
Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps N. Tan (Singapore, Singapore), Y. Ong (Singapore, Singapore), M. Mukherjee (Hamilton, Canada), S. Chao (Singapore, Singapore), W. Tan (Singapore, Singapore), M. Liew (Singapore, Singapore), X. Xu (Singapore, Singapore), Y. Sng (Singapore, Singapore), D. Wang (Singapore, Singapore), W. Wong (Singapore, Singapore), P. Nair (Hamilton, Canada), V. Angeli (Singapore, Singapore), H. Lim (Singapore, Singapore)
Rapid Benralizumab effectiveness in patients with severe eosinophilic asthma and bronchiectasis S. Nolasco (Catania, Italy), C. Crimi (Catania, Italy), R. Campisi (Catania, Italy), G. Cacopardo (Catania, Italy), R. Intravaia (Catania, Italy), M. Porto (Catania, Italy), N. Crimi (Catania, Italy)
Long term efficacy and safety of omalizumab in patients with allergic asthma-A real life study A. Papaioannou (Chaidari, Athens(Athens), Greece), M. Mplizou (Chaidari,(Athens), Greece), K. Porpodis (Thessaloniki, Greece), E. Fouka (Thessaloniki, Greece), E. Zervas (Athens, Greece), K. Samitas (Athens, Greece), M. Markatos (Chania, Greece), S. Papiris (Chaidari, Athens(Athens), Greece), M. Gaga (Athens, Greece), D. Papakosta (Thessaloniki, Greece), S. Loukides (Chaidari, Athens(Athens), Greece)
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy O. Elneima (Leicester, United Kingdom), W. Ibrahim (Leicester, United Kingdom), C. Boddy (Leicester, United Kingdom), A. Murphy (Leicester, United Kingdom), P. Bradding (Leicester, United Kingdom), C. Brightling (Leicester, United Kingdom), S. Siddiqui (Leicester, United Kingdom)
Super-response to dupilumab therapy in a patient with severe asthma and ABPA – a case report C. Mümmler (München, Germany), B. Kemmerich (München, Germany), K. Milger-Kneidinger (München, Germany)
Mepolizumab is effective in severe eosinophilic asthmatics: an Austrian real-life study. A. Renner (Wien, Austria), K. Marth (Wien, Austria), K. Patocka (Wien, Austria), W. Pohl (Wien, Austria)
Serum YKL-40 modulation in severe asthma patients treated with Mepolizumab D. Bagnasco (GENOVA (GE), Italy), A. Riccio (GENOVA (GE), Italy), L. De Ferrari (GENOVA (GE), Italy), M. Caminati (Verona, Italy), A. Massolo (Pisa, Italy), G. Senna (Verona, Italy), G. Passalacqua (GENOVA (GE), Italy)